Onderneming Bioqual, Inc. Other OTC
Aandelen
BIOQ
US09065J1016
Biotechnologie & Medisch Onderzoek
Vakgebied
Verkoop per activiteit
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Commercial and Other
82,6
%
| 54 | 81,6 % | 52 | 82,6 % | -4,06% |
National Institutes of Health
17,4
%
| 12 | 18,4 % | 11 | 17,4 % | -10,64% |
Verkoop per regio
USD in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 66 | 100,0 % | 63 | 100,0 % | -5,27% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Mark G. Lewis
CEO | Chief Executive Officer | 69 | 01-08-03 |
Charles C Kirk
DFI | Director of Finance/CFO | - | - |
Chief Tech/Sci/R&D Officer | - | 09-05-22 | |
Chief Operating Officer | - | - | |
Nancy A. Madden
ADM | Chief Administrative Officer | - | 01-01-03 |
Chander P. Sarma
CTO | Chief Tech/Sci/R&D Officer | - | 01-06-94 |
Director/Board Member | - | - |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 87 | 01-01-15 | |
Mark G. Lewis
CEO | Chief Executive Officer | 69 | 01-08-03 |
Director/Board Member | - | - | |
David B. Landon
BRD | Director/Board Member | 61 | 19-04-17 |
Director/Board Member | 86 | 01-01-91 | |
Director/Board Member | 68 | 01-01-92 | |
Director/Board Member | 48 | 25-07-18 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 1 599 408 | 894 416 ( 55,92 %) | 704 992 ( 44,08 %) | 55,92 % |
Bedrijfsgegevens
Sector
Verkoop per activiteit
Vaira. 1 jan. | Kapi. | |
---|---|---|
+40,80% | 53,67 mld. | |
-8,05% | 38,76 mld. | |
+35,79% | 38,86 mld. | |
-8,98% | 27,27 mld. | |
+10,69% | 25,91 mld. | |
-16,21% | 20,29 mld. | |
+31,00% | 12,78 mld. | |
+28,51% | 12,18 mld. | |
-1,67% | 11,96 mld. |